One vaccine may provide broad protection against many respiratory infections and allergens
Summary
Stanford Medicine reports on a universal intranasal vaccine candidate demonstrated in mice that protects against multiple respiratory viruses, bacteria, and allergens. The approach activates both innate and adaptive immunity via T cell signaling, using the GLA-3M-052-LS+OVA formulation; human trials could occur in 5-7 years with two-dose nasal delivery.